In vitro and in vivo study of water-soluble prodrugs of dexanabinol

Journal of Pharmaceutical Sciences

Volumn 88, Issue 11, 1999, Pages 1156-1160

  Pop, Emil ^a,b   Rachwal, Stanislaw ^a,c   Vlasak, Jirina ^a,b   Biegon, Anat ^d   Zharikova, Alevtina ^e   Prokai, Laszlo ^e  

^a Pharmos Corporation   (United States)

^b Alchem Laboratories Corporation   (United States)

^c NEUROGEN CORPORATION   (United States)

^d PHARMOS LTD   (Israel)

^e UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXANABINOL; PRODRUG;

ARTICLE; DRUG DISTRIBUTION; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TISSUE LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; RAT; TISSUE SPECIFICITY;

EID: 0032721494     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1021/js990098j     Document Type: Article

References (17)

1. Mechoulam, R.; Lander, N.; Bauer, A.; Zahalka, J. Synthesis of the individual, pharmacologically distinct, enantiomers of a tetrahydrocannabinol derivative. Tetrahedron: Asymmetry 1990, 1, 315-318.
2. Feigenbaum, J. J.; Bergmann, F.; Richmond, S. A.; Mechoulam, R.; Nadler, V.; Kloog, Y.; Sokolovsky, M. Nonpsychotropic cannabinoids act as a functional N-methyl-D-aspartate receptor blocker. Proc. Natl. Acad. Sci. U.S.A. 1989, 86, 9584-9587.
3. Eshhar, N.; Striem, S.; Kohen, R.; Tirosh, O.; Biegon., A. Neuroprotective and antioxidant activities of HU-211, a novel NMDA receptor antagonist. Eur. J. Pharmacol. 1995, 283, 1-3.
4. Shohami, E.; Novikov, M.; Mechoulam, R. A nonpsychotropic cannabinoid, HU-211, has cerebroprotective effects after closed head injury in the rat. J. Neurotrauma 1993, 10, 109-119.
5. Vered, M.; Bar Joseph, A.; Belyaev, L.; Biegon, A. Antiischemia activity of HU-211, a synthetic, nonpsychotropic cannabinoid. Acta Neurochir. 1994, 70 (suppl), 335-337.
6. Brewster, M. E.; Pop, E.; Foltz, R.; Griffith, W.; Amselem, S.; Biegon, A. Clinical Pharmacokinetics of Escalating I. V. Doses of Dexanabinol (HU-211), a Neuroprotectant Agent, in Normal Volunteers, J. Clin. Pharm. Ther. 1997, 35, 361-365.
7. Pop, E.; Brewster, M. E. Dimerization of Dexanabinol by Hydrogen Bonding Accounts for its Hydrophobic Character. Int. J. Quantum Chem. Quantum Biol. Symp. 24 1997, 65, 1057-64.
8. Pop, E.; Brewster, M. E.; Liu, Z. Z.; Soti, F.; Rachwal, S.; Dinculescu, A.; Nadler, V.; Barenholz, Y.; Mechoulam, R.; Biegon, A. A Water Soluble Prodrugs and Congeners of Dexanabinol. In Proceedings of the 1st World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Budapest, 1995; APGI: Châtenay Malabry, France, 1995; pp 127-128.
9. Pop, E.; Liu, Z. Z.; Brewster, M. E.; Barenholz, Y.; Korablyov, V.; Mechoulam, R.; Nadler, V.; Biegon, A. Derivatives of Dexanabinol. I. Water-soluble Salts of Glycinate Esters. Pharm. Res. 1996, 13, 62-69.
10. Pop, E.; Soti, F.; Brewster, M. E.; Barenholz, Y.; Mechoulam, R.; Nadler, V.; Biegon, A. Derivatives of Dexanabinol. II. Salts of Amino acid Esters Containing Tertiary and Quaternary Cyclic Nitrogen with Increased Water-Solubility. Pharm. Res. 1996, 13, 469-475.
11. Pop, E.; Soti, F.; Biegon, A.; Brewster, M. E. Allylic and Phenolic Phosphate Esters of Dexanabinol. Org. Prep. Proced. Int. 1997, 29, 341-347.
12. Partial results presented: Pop, E.; Rachwal, S.; Vlasak, J.; Brewster, M. E.; Prokai L.; Biegon, A. Quaternary Ammonium Moiety Containing Water Soluble Amino Acid Ester-Type Prodrugs of Dexanabinol. In Proceedings of the 2nd World Meeting on Pharmaceutics, Biopharmaceutics, and Pharmaceutical Technology, Paris, 1998; APGI: Châtenay Malabry, France, 1998; pp 101-102.
13. Pop, E.; Rachwal, B.; Rachwal S.; Vlasak J.; Prokai L.; Brewster, M. E. Synthesis of Labeled Dexanabinol, a Nonpsychotropic Cannabinoid with Neuroprotective Properties. J. Labeled Comp. Radiopharm. 1998, 15, 885-897.
14. Pop, E.; Rachwal, S. Unpublished results.
15. 9-Tetrahydrocannabinol, Naltrexone, and Their Active Metabolites in Plasma. Ther. Drug Monit. 1993, 15, 557-562.
16. Gibaldi M.; Perrier, D. Pharmacokinetics; Marcel Dekker: New York, 1982; p 48.
17. Biegon, A. Unpublished results.